NCT03900546

Brief Summary

This study evaluates the role of arterial tone in the accuracy of cardiac output (CO) measurement by Pressure Recording Analytical Method (PRAM). Patients receiving noradrenaline who need for clinical reason to change the noradrenaline dose will be enrolled. We use echocardiography as reference method of CO measurement.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Mar 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
5.1 years until next milestone

First Submitted

Initial submission to the registry

March 29, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 3, 2019

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

March 25, 2020

Status Verified

March 1, 2020

Enrollment Period

5.9 years

First QC Date

March 29, 2019

Last Update Submit

March 23, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes of cardiac output after variation of noradrenaline dose: ECO versus PRAM

    Agreement between echocardiography and PRAM in CO measurement during arterial tone changes induced by different dose of noradrenaline

    Before and 30 minutes after noradrenaline dose variation

Interventions

MostCareDEVICE

CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Critically ill patients admitted to intensive care unit that need variation of noradrenaline dose for clinical reason.

You may qualify if:

  • invasive blood pressure monitoring on site
  • need to start or change the dose of noradrenaline infusion for clinical reason

You may not qualify if:

  • age \<18
  • arrhythmia
  • severe valvular insufficiency
  • pregnancy
  • low quality arterial signal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Azienda Ospedaliero Universitaria Ospedali Riuniti Ancona

Ancona, Italy

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Abele Donati, MD, PhD

    Università Politecnica delle Marche

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 29, 2019

First Posted

April 3, 2019

Study Start

March 1, 2014

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

March 25, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

IPD will not be shared with other researchers.

Locations